Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management.

× No keyword cloud information.

26 in total

1. The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.

Authors: Dwight D Kloth; Lew Iacovelli; Rebecca Arbuckle; Angela C McIntosh
Journal: P T Date: 2010-04

2. Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study.

Authors: Gaurav Prakash; Pankaj Malhotra; Alka Khadwal; Deepesh Lad; Vikas Suri; Savita Kumari; Subhash Varma
Journal: Indian J Hematol Blood Transfus Date: 2017-09-30 Impact factor: 0.900

Review 3. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.

Authors: Frank R Brennan; Laura Dill Morton; Sebastian Spindeldreher; Andrea Kiessling; Roy Allenspach; Adam Hey; Patrick Y Muller; Werner Frings; Jennifer Sims
Journal: MAbs Date: 2010-05-23 Impact factor: 5.857

4. Microparticles and Nanoparticles Delivered in Intravenous Saline and in an Intravenous Solution of a Therapeutic Antibody Product.

Authors: Neha N Pardeshi; Wei Qi; Kevin Dahl; Liron Caplan; John F Carpenter
Journal: J Pharm Sci Date: 2016-11-07 Impact factor: 3.534

Review 5. The safety and side effects of monoclonal antibodies.

Authors: Trevor T Hansel; Harald Kropshofer; Thomas Singer; Jane A Mitchell; Andrew J T George
Journal: Nat Rev Drug Discov Date: 2010-03-22 Impact factor: 84.694

6. Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck.

Authors: Waseem Touma; Sami S Koro; Jessica Ley; Tanya M Wildes; Loren Michel; Yu Tao; Douglas Adkins
Journal: Oral Oncol Date: 2014-07-15 Impact factor: 5.337

7. Risk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials.

Authors: Na-Ping Tang; Hua Li; Yun-Liang Qiu; Guo-Min Zhou; Yan Wang; Jing Ma; Yan Chang; Qi-Bing Mei
Journal: Tumour Biol Date: 2014-07-23

8. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.

Authors: Manojkumar Bupathi; Joud Hajjar; Stacie Bean; Siqing Fu; David Hong; Daniel Karp; Bettzy Stephen; Kenneth Hess; Funda Meric-Bernstam; Aung Naing
Journal: Invest New Drugs Date: 2016-09-29 Impact factor: 3.850

9. Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study.

Authors: K M S Kanhai; R G J A Zuiker; I Stavrakaki; W Gladdines; P J Gaillard; E S Klaassen; G J Groeneveld
Journal: Br J Clin Pharmacol Date: 2018-03-09 Impact factor: 4.335

10. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab.

Authors: K A Foley; P F Wang; B L Barber; S R Long; J E Bagalman; V Wagner; X Song; Z Zhao
Journal: Ann Oncol Date: 2010-01-25 Impact factor: 32.976